RNA Analytical Quality/Resources

  1. Large Scale Purification Of Oligonucleotides With IEX 12/6/2024

    As oligonucleotide-based drugs gain momentum in therapeutic development, refining their manufacturing processes through solutions like ion exchange chromatography (IEX) becomes crucial.

  2. Engineered Enzymes Powering The Future Of mRNA Therapeutics 1/12/2026

    Optimizing RNA polymerase selection significantly improves mRNA yield and purity while reducing dsRNA. Discover how advanced enzyme engineering enhances therapeutic manufacturing efficiency and safety.

  3. Data Processing For Mass Confirmation, Impurities Analysis Of Oligos 5/5/2022

    Explore an automated, compliance-ready LC-MS workflow for intact mass confirmation and purity analysis of synthetic oligonucleotides including siRNA and large single guide RNA oligonucleotides.

  4. Boost LNP Drug Potency With Optimized Delivery Formulations 11/21/2022

    Lipid nanoparticles (LNPs) function as a drug delivery system for nucleic acids. Learn about the biomedical applications of LNPs as well as the anatomy, formulation optimization, and safety of LNPs.

  5. Analyzing Poly(A) Tails Of In Vitro Transcribed RNA 11/20/2025

    Find out how to achieve reliable IVT mRNA quality. Learn the best practices for precise analysis, including proper sample prep and system optimization for high-resolution results.

  6. Expectations On The Pathway To GMP For Gene-Modified Cell Therapies 6/21/2023

    Learn how a robust understanding of the RNP’s critical process parameters and CQAs is crucial for ensuring product consistency, enhancing patient safety, and maintaining regulatory compliance.

  7. Size Matters: Mastering Size Exclusion For Oligos 12/15/2025

    Learn how to separate molecules strictly by size, effectively remove salts, and select the correct pore specifications for a gentle, non-destructive purification workflow.

  8. Learn How Compliance-Ready LC-MS Workflows for Oligonucleotides Can Expand your Analytical Services Portfolio 2/22/2022

    CMO invests in solution to ensure data integrity and meet regulatory requirements as they expand their oligonucleotide manufacturing and analysis services.

  9. Unlocking The IP Benefits Of Novel Nucleases In CRISPR Therapies 10/28/2024

    Incorporating novel nucleases into CRISPR therapies enhances intellectual property benefits through improved licensing, strategic protections, and access to new gene targets.

  10. Nucleases - Are They A Problem For NAB Nanosep® Centrifugal Devices? 4/29/2022

    We examine whether the sample tubes and collection tubes of the NAB Nanosep centrifugal devices contain detectable amounts of DNase or RNase.